Multimodal Treatment Study of Children With Attention Deficit and Hyperactivity Disorder (MTA)
Status:
Completed
Trial end date:
1999-11-01
Target enrollment:
Participant gender:
Summary
This trial is a continuation of the Multimodal Treatment Study of Children with Attention
Deficit Hyperactivity Disorder (MTA Study). Continuation Aim 1 is to track the persistence of
intervention-related effects as the MTA sample matures into mid-adolescence, including
subsequent mental-health and school-related service utilization patterns as a function of MTA
treatment experience (treatment assignment) and outcome (degree of treatment success at 14
mo.). Aim 2 is to test specific hypotheses about predictors, mediators, and moderators of
long-term outcome among children with ADHD (e.g., comorbidity; family functioning; cognitive
skills; peer relations) that may influence adolescent functioning (either independent of or
through initial treatment assignment and/or 14-month treatment outcomes); and to compare how
these predictors, mediators, and moderators are similar or dissimilar within the normal
comparison group. Aim 3 is to track the patterns of risk and protective factors (including
their mediation or moderation by initial treatment assignment and/or outcome) involved in
early and subsequent stages of developing substance-related disorders and antisocial
behavior. Aim 4 is to examine the effect of initial treatment assignment and degree of
treatment success on later academic performance, achievement, school conduct, tendency to
drop out, and other adverse school outcomes.
In the original MTA design, patients were randomly assigned to 1 of 4 treatment conditions:
(1) medication only; (2) psychosocial only; (3) combined (medication and psychosocial); or
(4) Assessment-and-Referral condition. All but the latter were treated intensively for 14
months, with assessments for all subjects at baseline, 3, 9, 14, and 24 months. The original
MTA design thus provides short-term (10 months post-treatment) follow-up at 24 months. This
continuation extends the follow-up to assessments at 36, 60, and 84 months after treatment.
A child may be eligible for this study if he/she:
Is 7 - 9 years old, and has Attention Deficit Hyperactivity Disorder (ADHD).
Phase:
Phase 4
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health